ArticleCell biomaterials2026
Hybrid extracellular vesicles for targeted delivery of therapeutic cargoes to combat osteoporotic bone loss.
Article in Cell biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteoporosis arises from an imbalance between bone-resorbing osteoclasts and bone-forming osteoblasts, driving progressive bone loss. Here, we engineer bone-targeting hybrid vesicles by fusing extracellular vesicles with lipid nanoparticles to enable coordinated delivery of complementary therapeutics. These vesicles present and carry osteoprotegerin (OPG) protein and mRNA, and are fused with adenosine-loaded nanoparticles to form OPG-EV-LNP-Ado. Acting as a decoy for RANKL, OPG directs bone-specific targeting and uptake, enhancing delivery to osteoblasts. Systemic administration results in preferential bone accumulation and significantly attenuates osteoporotic pathology, demonstrating a modular platform for targeted, multi-cargo therapy to restore bone homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.